Conolidine’s analgesic outcomes stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors while in the central anxious method, conolidine modulates alternate molecular targets. A Science Developments analyze found that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://talibq787gtk8.blogginaway.com/profile